Why Heron Therapeutics Stock Is Crashing Today
Heron Therapeutics (NASDAQ: HRTX), a commercial-stage biotech developing medicines to address unmet medical needs, saw its shares drop by as much as 11.8% today on over five times the average daily volume. This double-digit move lower was sparked by a $150 million public offering of its common stock.
Heron reportedly plans on using the proceeds from this secondary offering to support the ongoing commercial launches of its medicines for chemotherapy-induced nausea, Sustol and Cinvanti, as well as to fund its clinical activities.
Image source: Getty Images.
Source: Fool.com
Heron Therapeutics Inc. Stock
€0.26
-3.480%
Our community is currently high on Heron Therapeutics Inc. with 4 Buy predictions and 1 Sell predictions.
With a target price of 3 € there is potential for a 1046.79% increase which would mean more than doubling the current price of 0.26 € for Heron Therapeutics Inc..
